SCHEMBL3674288

SCHEMBL3674288

O=C(c1cc[nH]c(=O)c1)N(CCC(F)(F)F)[C@@H]1COc2cccc(-c3cnc(C4CC4)nc3)c2C1

nearest known ligand 0.41

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 18/20 0.41
SCN5A Q14524 16/20 0.41
KCNH2 Q12809 12/20 0.41
SLC6A3 Q01959 1/20 0.37
GHSR Q92847 1/20 0.37
HTR1A P08908 2/20 0.34
SLC6A4 P31645 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL840415 0.82 SCN9A (0.44) SCN9ASCN5AKCNH2SLC6A3GHSR
SCHEMBL3670267 0.79 KCNH2 (0.45) SCN9ASCN5AKCNH2HTR1ASLC6A4
SCHEMBL3667613 0.79 SCN5A (0.38) SCN9ASCN5AKCNH2HTR1ASLC6A4
SCHEMBL3666273 0.77 SCN5A (0.49) SCN9ASCN5AKCNH2HTR1ASLC6A4
SCHEMBL839830 0.74 SCN9A (0.52) SCN9ASCN5AKCNH2SLC6A3GHSR
SCHEMBL840481 0.73 SCN9A (0.44) SCN9ASCN5AKCNH2SLC6A3GHSR
SCHEMBL840445 0.72 SCN9A (0.55) SCN9ASCN5AKCNH2SLC6A3GHSR
SCHEMBL840370 0.71 SCN9A (0.52) SCN9ASCN5AKCNH2SLC6A3GHSR
SCHEMBL840899 0.70 SCN9A (0.51) SCN9ASCN5AKCNH2SLC6A3GHSR
SCHEMBL840395 0.70 SCN9A (0.61) SCN9ASCN5AKCNH2SLC6A3GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2158198-A2 NOVEL N- (8HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN AstraZeneca AB (SE) 2010-03-03 EP disclosed
WO-2008130320-A2 NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2008-10-30 WO disclosed